+ Watch IGXT
on My Watchlist
In their own way, stocks are like people. Even the ugliest ones can find somebody to love them. When I dump all over a weak, lackluster micropharma like IntelGenx, I have to scratch my head when some goofball comes rushing in to defend the stock. Well, never fear because I'm not here to point out IntelGenx's bald spot or muffin top this time. I'm actually dropping a short-term outperform on the stub ahead of the February 3 PDUFA for VersaFilm Maxalt, which I think might generate enough interest for a modest run-up. Revenues from Forfivo XL have been predictably pathetic but IntelGenx seems to have adapted to survival in financially anaerobic conditions.
Optimist on going above 1 dollar within 1-2 year
Strong fundamentals here.. One of the cheapest Biotech Stock out there !1)Very Very low Market cap of $23.5 M2) Mega drug Pipeline of 9 Products including a potential Blockbuster3) 2 New NDA filing in 20124) NO DEBT5)Cash till 20146) Very strong Institutions and Insider in this stock7) low float StockIntelgenx (IGXT.OB)Market Cap : $26.1 MPrice: 0.56IntelGenx Announces FDA Approval of Its High Dose Anti-Depressant CPI-300http://finance.yahoo.com/news/IntelGenx-Announces-FDA-pz-4172746127.html?x=0&l=1Company Presentationhttp://www.intelgenx.com/_assets/pdf/Intelgenx-Presentation.pdfOwnershiphttp://data.cnbc.com/quotes/IGXT.OB/tab/8interview with ceozerbehttp://www.cantechletter.com/2010/12/cantech-letter-interviews-horst-zerbe-president-and-ceo-of-intelgenx/Articlehttp://www.biomedreports.com/2011111183312/fda-spproval-is-a-game-changer-for-intelgen
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions